OncologyOnline.net

Oncology Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Mediexplorer.it

According to phase II trial PRINCEPS, no safety signals were raised, no major toxicity and no surgery impairment were reported following one cycle of neoadjuvant Atezolizumab ( Tecentriq ) therapy in ...


Entrectinib ( Rozlytrek ) is a potent, selective, CNS active, ROS1 tyrosine kinase inhibitor ( TKI ). In a preliminary analysis ( data cut-off: 31 May 2018 ) of patients with ROS1 fusion-positive ( ...


Pembrolizumab ( Keytruda ) plus Olaparib ( Lynparza ) has shown antitumor activity and acceptable safety in Docetaxel-pretreated pts with metastatic castration-resistant prostate cancer ( mCRPC ) enro ...


The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake research to identify biomarkers of response and resis ...


Ibrutinib ( Imbruvica ), a once-daily Bruton’s tyrosine kinase ( BTK ) inhibitor approved for various B-cell malignancies, also inhibits other kinases, such as ITK and ETK ( Wang Clin Cancer Res 2018 ...


Preclinical evidence has suggested that Niraparib ( Zejula ), a poly (ADP-ribose) polymerase inhibitor, may synergise with PD-1 inhibitors. Pembrolizumab ( Keytruda ) is a PD-1 inhibitor approved a ...


MET exon 14 skipping mutations ( METex14 ) are seen in 3-4% of patients with non-small cell lung cancer ( METex14 NSCLC ) and are associated with poor outcomes. In the phase 2 GEOMETRY mono-1 stud ...


The phase III SPARTAN study evaluated Apalutamide ( Erleada ) vs Placebo in patients with non-metastatic castration-resistant prostate cancer ( nmCRPC ) who had prostate-specific antigen doubling time ...


There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small cell lung cancer ( NSCLC ) and high programmed death-ligand ...


Non-clear cell renal cell carcinoma ( nccRCC ) encompasses a heterogenous group of histologies comprising approximately 25% of all renal cell carcinoma ( RCC ) diagnoses with worse outcomes than clear ...


Castration-resistant prostate cancer ( CRPC ) is defined as disease progression during ADT ( androgen deprivation therapy ), with serum testosterone at castrate levels. The absence of metastases ( M0 ...


Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of adjuvant therapy with Dabrafenib ( Tafinlar ) plus Trametinib ( Mekinis ...


RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers ( NSCLCs ). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET inhibition are unknown. ...


Among patients with non–small-cell lung cancer ( NSCLC ), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib ( Tabrecta ), a selective inhibitor of t ...


A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer ( NSCLC ). Researchers have evalua ...